Q3 Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Q3 Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-47,249	Closed	-$5.76M	–	91
2025 Q4	$5.76M	Buy	+47,249	New	+$5.42M	1.32%	13
2020 Q1	–	Sell	-39,881	Closed	-$3.79M	–	42
2019 Q4	$3.79M	Buy	+39,881	New	+$3.45M	8.54%	5
2019 Q2	–	Sell	-1,137,741	Closed	-$3.29M	–	43
2019 Q1	$3.29M	Buy	+1,137,741	New	+$96.8M	8.85%	3
2018 Q3	–	Sell	-61,243	Closed	-$5.83M	–	38
2018 Q2	$5.83M	Sell	61,243 -662	-1%	-$60.8K	6.4%	5
2018 Q1	$5.43M	Buy	+61,905	New	+$5.65M	6.14%	6

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Q3 Asset Management's XBI Position: Q1 2026 in Review

Q3 Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 47,249 shares — an estimated $5.76M sold.

Q3 Asset Management first reported a position in XBI in Q1 2018 and held it in 5 quarters. The position peaked at $5.83M in Q2 2018. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Q3 Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Q3 Asset Management sold 47,249 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $5.76M.
Q3 Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and held it in 5 quarters.
Q3 Asset Management's State Street SPDR S&P Biotech ETF position peaked at $5.83M in Q2 2018.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Q3 Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.